FDA warned Slendid that its website sells compounded semaglutide and tirzepatide with a false "clinically proven" claim, making the drugs misbranded.
What happened
FDA reviewed the company's website at https://slendid.com in August 2025 and saw that it offers various compounded drug products, including semaglutide and tirzepatide. The site states "Clinically proven weight loss treatments," which FDA says implies the compounded products are the same as an FDA-approved drug when compounded drugs are not FDA-approved. FDA calls that claim false or misleading, which makes the products misbranded.
What FDA found
The website says the products are "Clinically proven weight loss treatments," which falsely suggests they are the same as an FDA-approved drug.
FDCA section 502(a) [21 U.S.C. § 352(a)]Advertising a compounded drug with a false or misleading claim makes that drug misbranded.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]Sending these misbranded drugs across state lines is a prohibited act.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]The semaglutide and tirzepatide products are "new drugs" because they are not generally recognized as safe and effective for their labeled uses.
FDCA section 201(p) [21 U.S.C. § 321(p)]
What FDA wants
FDA tells the company to take immediate action, including stopping use of the cited "clinically proven" language, and to send a written response within 15 working days describing the specific steps taken and how repeat violations will be prevented. If the company believes it is not in violation, it must explain why and provide supporting information.
Who should pay attention
- telehealth and online weight-loss platforms selling compounded GLP-1 drugs
- compounding pharmacies and the people who write their website copy
- marketing and compliance teams that review prescription drug promotional claims
This is a summary. Read the original letter on fda.gov.